- Home
- Drugs
- Prescription drugs
- Opticef Suspension, granules for suspension, 100 ml (53 g) in a bottle.
Prescription-Only Medicine
Opticef Suspension, granules for suspension, 100 ml (53 g) in a bottle.
Antibacterial
J01DD08 – Antibacterial agents for systemic use. Beta-lactam antibiotics. Third-generation cephalosporins.
5 mL of the preparation contains 100 mg of cefixime.
- Infections of the upper respiratory tract (including otitis media) and other upper respiratory tract infections (such as sinusitis, pharyngitis, tonsillitis of bacterial etiology) in cases of known or suspected resistance of the pathogen to other commonly used antibiotics, or when there is a risk of treatment failure.
- Infections of the lower respiratory tract (including acute bronchitis and exacerbation of chronic bronchitis).
- Infections of the urinary tract (including cystitis, cystourethritis, uncomplicated pyelonephritis).
53 g of granules in a brown glass bottle, 1 bottle with a measuring spoon in each package.
Pharmacological Properties.
Cefixime – a third-generation cephalosporin antibiotic for systemic use. In vitro, it exhibits significant bactericidal activity against a broad spectrum of Gram-positive and Gram-negative microorganisms. Clinically effective in the treatment of infections caused by common pathogenic microorganisms, including Streptococcus pneumoniae, Streptococcus pyogenes, E. coli, Proteus mirabilis, Klebsiella species, Haemophilus influenzae (both beta-lactamase-positive and -negative), Branhamella catarrhalis (both beta-lactamase-positive and -negative), and Enterobacter species. Cefixime has a high degree of stability in the presence of beta-lactamases.
Most strains of enterococci (Streptococcus faecalis, Enterococci group D) and staphylococci (including coagulase-positive, coagulase-negative, and methicillin-resistant strains) are resistant to cefixime. Additionally, most strains of Pseudomonas, Bacteroides fragilis, Listeria monocytogenes, and Clostridia are resistant to cefixime.
Dosage and Administration.
Food intake does not affect the absorption of cefixime. The usual treatment course is 7 days, but if necessary, it can be extended to 14 days. For uncomplicated cystitis, the treatment course is 3 days.
Children aged 6 months to 10 years (with a body weight of up to 50 kg): the recommended dose is 8 mg/kg per day, either as a single dose or 4 mg/kg every 12 hours, depending on the severity of the condition.
Adults and children aged 10 years and older (or with a body weight greater than 50 kg): the recommended dose is 400 mg once daily or 200 mg every 12 hours, depending on the severity of the condition.
Elderly patients: prescribe the recommended adult dose. Monitor kidney function and adjust the dose in case of severe renal impairment (see “Renal Impairment”).
Renal Impairment: Cefixime can be used in cases of impaired kidney function. For patients with a creatinine clearance of 20 ml/min or higher, the standard dose and dosing regimen should be prescribed. For patients with a creatinine clearance below 20 ml/min, the daily dose should be reduced by 50%. This also applies to patients on continuous ambulatory peritoneal dialysis or hemodialysis.
Preparation of Suspension.
For internal use only.
For 60 ml suspension (100 mg/5 ml): shake the bottle several times before reconstitution. Add 40 ml of cooled, boiled water at room temperature in two portions and shake until a homogeneous suspension forms.
For 100 ml suspension (100 mg/5 ml): shake the bottle several times before reconstitution. Add 66 ml of cooled, boiled water at room temperature in two portions and shake until a homogeneous suspension forms. Shake the prepared suspension thoroughly before each use. Measure the dose using the measuring spoon provided.
Children:
The drug is used in children aged 6 months and older. The safety and efficacy of cefixime in children under 6 months of age have not been established, so its use in this category of patients is not recommended.
See also – OPTICEF Suspension, Granules for Oral Use, 60 ml (32 g) – AGROPHARM